pyoluteorin has been researched along with Hematologic Malignancies in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Amin, S; Claxton, D; Doi, K; Dower, C; Gowda, K; Lin, JM; Liu, Q; Loughran, TP; Sung, SS; Wang, HG | 1 |
1 other study(ies) available for pyoluteorin and Hematologic Malignancies
Article | Year |
---|---|
Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Female; Hematologic Neoplasms; Humans; Models, Molecular; Molecular Conformation; Myeloid Cell Leukemia Sequence 1 Protein; Phenols; Protein Binding; Protein Interaction Domains and Motifs; Proteolysis; Pyrroles; Stromal Cells; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |